In the context of global climate change, countries are actively advocating the construction of a green, low-carbon and recycling economic system and promoting high-quality development and high-efficiency governance. Environmental, social and corporate governance (ESG) , which is in line with the concept of sustainable development, has been widely concerned by the international community, and ESG disclosure is the foundation of ESG development. The biomedical industry is one of the strategic high points of international science and technological and economic competition. Improving corporate disclosure is of great significance to enhance corporate competitiveness, reduce the risks of corporate, improve corporate performance and thus achieve sustainable development of the biomedical industry. Taking the listed companies in the ESG rating report of Runling Global Biomedical Sector from 2020 to 2022 as samples, this paper makes an objective analysis of the disclosed ESG-related reports, and finds that there are some problems in the development of ESG in Chinas biomedical industry, such as low disclosure rate and level, diverse disclosure standards, imperfect disclosure indicators and qualitative indicators. In this paper, an enterprise is selected as a specific research object, uses the case study method, and its disclosure report is compared with the key core issues of Runling Global Ratings by case analysis, so as to improve the core issues of ESG disclosure in the biopharmaceutical industry in light of the common problems that exist in the industrys disclosure of information. In the future, the development of ESG in the biopharmaceutical industry should improve the disclosure rate of enterprises and the disclosure level of ESG reports; unify the compilation standard of ESG reports; reasonably allocate the disclosure proportion of enterprise indicators, and try to make each indicator quantitative.
